Telix Pharmaceuticals Receives FDA Response on TLX250-CDx Application

Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.

Telix Pharmaceuticals announced it received a Complete Response Letter from the U.S. FDA regarding its Biologics License Application for TLX250-CDx, a PET agent for diagnosing renal masses. The FDA identified deficiencies in the Chemistry, Manufacturing, and Controls package, requiring additional data and remediation of issues with third-party partners. Despite these setbacks, Telix plans to address the concerns promptly and believes the issues are resolvable. The announcement does not affect the company’s 2025 revenue guidance, as it excludes unapproved products, and Telix will continue providing patient access through an FDA-approved expanded access program.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$25.60 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, the company operates internationally in the United States, United Kingdom, Brazil, Canada, Europe, and Japan. Telix is dedicated to addressing significant unmet medical needs in oncology and rare diseases.

Average Trading Volume: 1,925,010

Technical Sentiment Signal: Sell

Current Market Cap: A$6.41B

For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.